Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg

Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as "Zydus") has received NOC (Notice of Compliance) from Health Canada for generic Liothyronine tablets 5 mcg and 25 mcg.

Liothyronine tablets, a synthetic form of the thyroid hormone T3 (triiodothyronine), are primarily indicated for treating hypothyroidism.

ZDS - Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ. Liothyronine tablets had annual sales of 10.9 mn CAD (Canadian Dollars) in Canada (IQVIA MAT June 2025).

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 994.30 as compared to the previous close of Rs. 988.75. The total number of shares traded during the day was 19541 in over 1996 trades.

The stock hit an intraday high of Rs. 997.00 and intraday low of 975.20. The net turnover during the day was Rs. 19270158.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals Approval HealthCanada LiothyronineTablets